Plain-English translation of NCT06251076 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a pilot study testing how to give , a new medication for multiple myeloma, safely in an outpatient clinic instead of a hospital. The study will enroll 15 patients across two cancer centers and also ask their caregivers about the impact of this arrangement on their lives. Researchers want to figure out the best, safest way to deliver this treatment in a community setting.
is a promising new treatment for patients whose myeloma has stopped responding to other medications, but it usually requires close monitoring in a hospital setting. This study aims to see if the treatment can be given safely in an outpatient clinic, which would be more convenient for patients and their families.
You likely qualify if…
You likely don't qualify if…
Participants will receive the medication through a carefully planned step-up dosing schedule at one of two cancer centers (Princess Margaret or Southlake Regional). Some participants may also receive an additional medication to help prevent side effects. Throughout the process, your caregiver will be asked to complete questionnaires about how the outpatient arrangement is affecting them and your family. The study is designed to help researchers understand the best way to deliver this treatment in a clinic setting while minimizing burden on patients and caregivers.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
Canada